{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:56:06Z","timestamp":1780887366091,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,2]],"date-time":"2017-01-02T00:00:00Z","timestamp":1483315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10620-016-4395-8","type":"journal-article","created":{"date-parts":[[2017,1,2]],"date-time":"2017-01-02T11:54:46Z","timestamp":1483358086000},"page":"441-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet\u2019s Disease Treated with Infliximab"],"prefix":"10.1007","volume":"62","author":[{"given":"Jun","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Nian","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-fei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-long","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,2]]},"reference":[{"key":"4395_CR1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0049-0172(79)90004-0","volume":"8","author":"T Shimizu","year":"1979","unstructured":"Shimizu T, Ehrlich GE, Inaba G, et al. Behcet disease (Behcet syndrome). Semin Arthritis Rheum. 1979;8:223\u2013260.","journal-title":"Semin Arthritis Rheum"},{"key":"4395_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/gut.18.6.491","volume":"18","author":"T Lehner","year":"1977","unstructured":"Lehner T. Oral ulceration and Behcet\u2019s syndrome. Gut. 1977;18:491\u2013511.","journal-title":"Gut"},{"key":"4395_CR3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, et al. Behcet\u2019s disease. N Engl J Med. 1999;341:1284\u20131291.","journal-title":"N Engl J Med"},{"key":"4395_CR4","doi-asserted-by":"crossref","first-page":"17171","DOI":"10.3748\/wjg.v20.i45.17171","volume":"20","author":"J Zou","year":"2014","unstructured":"Zou J, Shen Y, Ji DN, et al. Endoscopic findings of gastrointestinal involvement in Chinese patients with Behcet\u2019s disease. World J Gastroenterol.. 2014;20:17171\u201317178.","journal-title":"World J Gastroenterol."},{"key":"4395_CR5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0046-8177(85)80250-1","volume":"16","author":"S Lakhanpal","year":"1985","unstructured":"Lakhanpal S, Tani K, Lie JT, et al. Pathologic features of Behcet\u2019s syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985;16:790\u2013795.","journal-title":"Hum Pathol"},{"key":"4395_CR6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02604297","volume":"24","author":"Y Kasahara","year":"1981","unstructured":"Kasahara Y, Tanaka S, Nishino M, et al. Intestinal involvement in Behcet\u2019s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum. 1981;24:103\u2013106.","journal-title":"Dis Colon Rectum"},{"key":"4395_CR7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/archsurg.1980.01380060057016","volume":"115","author":"LL Ketch","year":"1980","unstructured":"Ketch LL, Buerk CA, Liechty D. Surgical implications of Behcet\u2019s disease. Arch Surg. 1980;115:759\u2013760.","journal-title":"Arch Surg"},{"key":"4395_CR8","first-page":"2848","volume":"95","author":"M Naganuma","year":"2000","unstructured":"Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet\u2019s disease. Am J Gastroenterol. 2000;95:2848\u20132851.","journal-title":"Am J Gastroenterol"},{"key":"4395_CR9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","volume":"49","author":"SP Travis","year":"2001","unstructured":"Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet\u2019s syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49:725\u2013728.","journal-title":"Gut"},{"key":"4395_CR10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61\u201370.","journal-title":"Semin Arthritis Rheum"},{"key":"4395_CR11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","volume":"52","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behcet\u2019s disease refractory to conventional medication. Intern Med. 2013;52:1855\u20131862.","journal-title":"Intern Med"},{"key":"4395_CR12","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833\u20131838.","journal-title":"Inflamm Bowel Dis"},{"key":"4395_CR13","first-page":"59","volume":"10","author":"Y Mizushima","year":"1988","unstructured":"Mizushima Y. Recent research into Behcet\u2019s disease in Japan. Int J Tissue React. 1988;10:59\u201365.","journal-title":"Int J Tissue React"},{"key":"4395_CR14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2011;17:605\u2013613.","journal-title":"Inflamm Bowel Dis"},{"key":"4395_CR15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621\u2013630.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4395_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Behcet\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"key":"4395_CR17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol. 2014;49:156\u2013162.","journal-title":"J Gastroenterol"},{"key":"4395_CR18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","volume":"138","author":"F Baert","year":"2010","unstructured":"Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease. Gastroenterology. 2010;138:463\u2013468. quiz e10-1.","journal-title":"Gastroenterology"},{"key":"4395_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ibd.22977","volume":"19","author":"P Cruz De","year":"2013","unstructured":"De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn\u2019s disease: a systematic review. Inflamm Bowel Dis. 2013;19:429\u2013444.","journal-title":"Inflamm Bowel Dis"},{"key":"4395_CR20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.25.6.665","volume":"25","author":"P Rutgeerts","year":"1984","unstructured":"Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn\u2019s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665\u2013672.","journal-title":"Gut"},{"key":"4395_CR21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","volume":"99","author":"P Rutgeerts","year":"1990","unstructured":"Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn\u2019s disease. Gastroenterology. 1990;99:956\u2013963.","journal-title":"Gastroenterology"},{"key":"4395_CR22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0016-5107(99)80017-0","volume":"50","author":"G D\u2019Haens","year":"1999","unstructured":"D\u2019Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn\u2019s (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999;50:667\u2013671.","journal-title":"Gastrointest Endosc"},{"key":"4395_CR23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"4395_CR24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805\u20131812.","journal-title":"J Clin Invest"},{"key":"4395_CR25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00296-007-0357-y","volume":"27","author":"P Emery","year":"2007","unstructured":"Emery P, Gabay C, Kraan M, et al. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007;27:793\u2013806.","journal-title":"Rheumatol Int"},{"key":"4395_CR26","first-page":"73","volume":"32","author":"HL Johnson","year":"1999","unstructured":"Johnson HL, Chiou CC, Cho CT. Applications of acute phase reactants in infectious diseases. J Microbiol Immunol Infect. 1999;32:73\u201382.","journal-title":"J Microbiol Immunol Infect"},{"key":"4395_CR27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","volume":"35","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn\u2019s disease: a post hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568\u2013576.","journal-title":"Aliment Pharmacol Ther"},{"key":"4395_CR28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2036.2011.04827.x","volume":"34","author":"LS Kiss","year":"2011","unstructured":"Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn\u2019s disease. Aliment Pharmacol Ther. 2011;34:911\u2013922.","journal-title":"Aliment Pharmacol Ther"},{"key":"4395_CR29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MEG.0b013e32835558cf","volume":"24","author":"LY Lee","year":"2012","unstructured":"Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol. 2012;24:1078\u20131085.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4395-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-016-4395-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4395-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:07:25Z","timestamp":1498374445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-016-4395-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["4395"],"URL":"https:\/\/doi.org\/10.1007\/s10620-016-4395-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,2]]}}}